Brian J Mickey, MD, PhD

Brian J. Mickey is Associate Professor of Psychiatry. He studied physics and biology at the University of Washington, Seattle. He then completed the Medical Scientist Training Program at the University of Michigan, Ann Arbor, where he earned his MD and PhD in Neuroscience. After psychiatry residency and postdoctoral fellowship at the Molecular & Behavioral Neuroscience Institute, he joined the faculty at the University of Michigan. In 2015, he moved to the University of Utah, where he is a faculty member in Psychiatry, Neuroscience, and Bioengineering.

Dr. Mickey is board-certified in Psychiatry. His clinical focus is treatment-resistant mood disorders. He is a provider of pharmacologic treatments and brain stimulation interventions, including electroconvulsive therapy (ECT) and transcranial magnetic stimulation therapy (TMS). His research group is using brain imaging and genetics in human subjects to study neurobiological mechanisms that underlie individual differences in mood and motivation, and the causes of treatment resistance.



Tiffany Love, PhD

Tiffany Love’s research utilizes neuroimaging technology to explore the relationships between neural activity, motivation, and social interaction and how these relationships can be affected by psychiatric illness. Her academic interests center on understanding the neurobiological mechanisms that underlie drug use, abuse and risk.

During Dr. Love’s graduate work, she observed that common genetic variants in the oxytocin gene are associated with differential neural responses to salient events as measured by [11C]-raclopride positron emission tomography (PET). This study was the first to demonstrate a link between oxytocin gene variation and dopaminergic responsiveness in humans. During her postdoctoral research she chose to more directly ascertain oxytocin’s effect on motivational processes by utilizing a powerful neuroimaging technique, pharmacological fMRI.

Pharmacological fMRI combines drug administration in conjunction with scanning and, as such, we can observe the influence a given drug has on neural activity. As Dr. Love currently holds an investigator sponsored-IND from the Food and Drug Administration (FDA) for an intranasal form of oxytocin, she am able to explore how oxytocin shapes neural activity within motivational networks using this technique.

Dr. Love’s current experiments seek to establish whether oxytocin administration can modulate activity in the neural circuits responsible for the processing of rewards and effect social and other reward-driven behavior.

Visit Dr. Love’s website at for more information about her lab and research.



Jon-Kar Zubieta, MD, PhD

Jon-Kar Zubieta is currently the William H. and Edna Stimson Presidential Endowed Chair of Psychiatry. He completed an M.D. (1986) and a Ph.D. in Neurosciences (1992) at the Universidad del Pais Vasco, Bilbao, Vizcaya, Spain and finished his Psychiatry residency [Research track] (1993) while training as both a clinical and research fellow in Nuclear Medicine (1993) at the University of Michigan Medical School. He completed a second clinical/research fellowship in Nuclear Medicine at Johns Hopkins, where he served as Chief Resident (1995). Prior to joining the psychiatry faculty at the University of Utah School of Medicine, he held the appointment of Phil F. Jenkins Endowed Professor of Psychiatry as well as a Professor of Radiology at the University of Michigan Medical School. He was also Research Professor at the Molecular and Behavioral Neuroscience Institute in Ann Arbor, MI. He is board-certified in Psychiatry by the American Board of Psychiatry and Neurology and in Nuclear Medicine by the American Board of Nuclear Medicine.

His academic work has focused primarily on the mood disorders. His research utilizes functional and molecular imaging in combination with genetic and psychophysical information to understand inter-individual differences in neurobiological mechanisms underlying emotion and stress regulation in humans. This work has led to over 200 original publications and book chapters covering multiple areas of overlapping enquiry. These include studies on the pathophysiology of Major Depression, Bipolar Disorder and other emotion dysregulation disorders, and their relationship with clinical presentations and outcomes; developmental and adult neurobiological mechanisms associated with substance use disorders, as well as the study of comorbid conditions, such as persistent pain syndromes. Recent work has also examined the neurobiological mechanisms underlying placebo effects as a model to study human resiliency mechanisms.

With his strong background and training in the neurosciences, psychiatry and nuclear medicine, Dr. Zubieta is dedicated to promoting innovation at the nexus of patient care and scientific discovery.


Robert C. Welsch, PhD

Dr. Welsh’s research interests are centered on advanced analytic and mathematical approaches to understanding brain structure and function in diseased states. He uses neuroimaging methodology such as diffusion imaging (DTI/HARDI), resting state connectivity, as well as activation paradigms to further his studies. Using these techniques, he has investigated diseases such as schizophrenia, obsessive compulsive disorder, post-traumatic brain disorder, and amyotrophic lateral sclerosis. He currently is building analytic models for development of biomarkers based on multi-modal neuroimaging data. These models are being realized in various machine learning algorithms. In the past, while he was at the University of Michigan, he was involved in pre-surgical planning in collaborations with clinicians from radiation-oncology, neurosurgery, and neurology.


Russell S. Richardson, PhD

Dr. Richardson is the Marjorie Rosenblatt Goodman and Jack Goodman Family Professor of Geriatrics in the University of Utah School of Medicine and Professor, Department of Nutrition and Integrative Physiology, as well as an Adjunct Professor in the Department of Physical Therapy in the College of Health. Additionally, he is the Associate Director for the VA Salt Lake City Geriatric Research, Education, and Clinical Center. Dr. Richardson is the founder and Director of the Utah Vascular Research Laboratory (UVRL) for which the major mission is to elucidate the impact of age and age-related disease on skeletal muscle vascular and metabolic control / function with a strong emphasis on the implications for physical function and mobility. Dr. Richardson has worked on a wide variety of integrative physiologic studies for over 25 years. Throughout this time period he has been continuously externally funded and successfully mentored well over 30 people at the Graduate and Post Doctoral level. The unique environment that has evolved as a consequence of these experiences and the highly collaborative nature of the University of Utah has contributed to success of Dr. Richardson and the UVRL.


Craig J. Bryan, PsyD

Dr. Craig J. Bryan, PsyD, ABPP, is a board-certified clinical psychologist in cognitive behavioral psychology, and is currently the Executive Director of the National Center for Veterans Studies at The University of Utah. Dr. Bryan received his PsyD in clinical psychology in 2006 from Baylor University, and completed his clinical psychology residency at the Wilford Hall Medical Center, Lackland Air Force Base, TX. He was retained as faculty in the Department of Psychology at Wilford Hall Medical Center, where he was Chief of the Primary Care Psychology Service, as well as the Suicide Prevention Program Manager for Lackland AFB. Dr. Bryan deployed to Balad, Iraq, in 2009, where he served as the Director of the Traumatic Brain Injury Clinic at the Air Force Theater Hospital. Dr. Bryan separated from active duty service shortly after his deployment, and currently researches suicidal behaviors and suicide prevention strategies, and psychological health and resiliency. He currently manages numerous federally-funded projects in excess of $10 million, to include studies testing cognitive behavioral treatments for suicidal service members, developing innovative methods to identify and detect high-risk military personnel and veterans, and disseminating effective treatments to health care providers and the public.

Dr. Bryan has published over 120 scientific articles and several books including Managing Suicide Risk in Primary Care, Cognitive Behavioral Therapy for Preventing Suicide Attempts: A Guide to Brief Treatments Across Clinical Settings, and the Handbook of Psychosocial Interventions for Veterans and Service Members: A Guide for the Non-Military Mental Health Clinician. He is the lead risk management consultant for the $25 million STRONG STAR Research Consortium and the $45 million Consortium to Alleviate PTSD, which investigates treatments for combat-related PTSD among military personnel, and has served on the Board of Directors of the American Association for Suicidology. He is considered leading national expert on military and veteran suicide. For his contributions to military mental health and suicide prevention, Dr. Bryan has received numerous awards and recognitions including the Arthur W. Melton Award for Early Career Achievement, the Peter J.N. Linnerooth National Service Award, and the Charles S. Gersoni Military Psychology Award from the American Psychological Association; and the Edwin S Shneidman Award for outstanding contributions to research in suicide from the American Association of Suicidology.


Vincent Koppelmans, PhD

Vincent Koppelmans, PhD, is joining the Department of Psychiatry faculty as a Research Assistant Professor. Dr. Kopplemans earned a Master of Science degree in Clinical Neuropsychology from the VU University, Amsterdam, the Netherlands, and a Master of Science degree in Health Sciences from the Erasmus University, Rotterdam, the Netherlands. He obtained his PhD in Neuro-epidemiology from the same Erasmus University for his dissertation on The Late Effects of Adjuvant Chemotherapy on Brain Function and Structure.

Dr. Koppelmans completed his postdoctoral training in Neural Control of Movement in the Department of Kinesiology at the University of Michigan in Ann Arbor, MI. He was awarded a fellowship from the National Space Biomedical Research Institute to investigate exercise as a potential countermeasure for brain changes that occur as a result of long-duration bed rest. Following his postdoctoral training, he joined the Kinesiology Department of the University of Michigan as an Assistant Research Scientist. He is interested in disease and age related brain structural and functional neuroplasticity and their relation with cognitive function and motor behavior.


Scott A Langenecker, PhD

Scott A. Langenecker, Ph.D. is a clinical neuropsychologist and Associate Professor of Psychiatry and Psychology. He is a native of rural Wisconsin, and completed his undergraduate work at the University of Wisconsin at Madison. Dr. Langenecker completed his graduate work at Marquette University with a dissertation on life span studies of inhibitory control, with focus on healthy aging and functional MRI, winning an APA dissertation award. He completed his internship at the Albert Einstein North Shore-Long Island Jewish Medical Center in New York. Dr. Langenecker’s fellowship was at the University of Michigan Medical Center in Clinical Neuropsychology, which he completed in 2003, and he was a faculty member at the University of Michigan until July, 2012. He is now the Director of Cognitive Neuroscience at the University of Illinois at Chicago, and Associate Professor with tenure in psychology and psychiatry. He has been actively involved in the Prechter Longitudinal Study of Bipolar Disorder since its inception in 2005.

Dr. Langenecker’s research and clinical work focuses on the translational cognitive neuroscience of mood disorders across the lifespan. Specifically, he is involved in studies to understand the cognitive and affective abnormalities observed in depression and bipolar disorder, the neurological (fMRI, PET) underpinnings of these abnormalities, and the ramifications for treatment selection and prognosis. Toward this end, he uses, modifies and develops neuroimaging studies with cognitive and affective challenge paradigms that can be used as translational neuropsychological measures and be administered in clinical settings. Thus, relationships between performance parameters collected in clinical and research settings, and activation (fMRI) and/or binding (PET) measures can offer increased insight into the nature, etiology, and treatment response of mood disorders. Using these strategies to identify depression and bipolar subtypes (e.g., based upon treatment prediction/response, clinical features, behavioral measures, or neural systems parameters) is a key approach toward reducing the negative impact of mood disorders. His current work is focused on the late adolescent translational period in which risk for mood disorders is at a peak.